MedTrace Logo

Phase II Prospective Trial of Addition of Rituximab to Reduced Dose CHOP Chemotherapy in DLBC L Patients Aged 65 Years and Over

NCT02792491 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2016-06-09

No results posted yet for this study

Summary

This is Phase II prospective trial of addition of rituximab to reduced dose CHOP chemotherapy in DLBC L patients aged 65 years and over.

Conditions

  • Diffuse Large B-cell Lymphoma

Interventions

DRUG

Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone

Reduced dose of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone

Sponsors & Collaborators

  • Pusan National University Hospital

    lead OTHER

Principal Investigators

  • Ho-Jin Ho-Jin · Pusan National University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2017-12-31
Completion
2017-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02792491 on ClinicalTrials.gov